Company intelligence / Profile preview

Parallel Bio

Cambridge, Massachusetts, United Statesparallel.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has tested over 75 drugs in their Clinical Trial in a Dish platform with results matching clinical data. They have discovered eight human high-affinity antibodies for cancer and infectious diseases.

Therapeutic areas: OtherOncologyImmunologyInfectious Diseases
Modalities: Immunotherapiesantibodiesvaccines
Industry: Biotech

Partnerships

Five pharmaceutical companies including a Fortune 500 firm, testing 20 drug candidates

Beyond the preview

Go deeper on Parallel Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parallel Bio.

Explore the full profile